Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder

References

• Murakami JM, Essayli JH, Latner JD. The relative stigmatization of eating disorders and obesity in males and females. Appetite. 2016 Jul 01;102:77–82.
   PubMed Web of Science ®Google Scholar
• Puhl R, Suh Y. Stigma and eating and weight disorders. Curr Psych Rep. 2015 Mar;17(3):552.
   PubMed Web of Science ®Google Scholar
• Thompson-Brenner H, Satir DA, Franko DL, et al. Clinician reactions to patients with eating disorders: a review of the literature. Psych Serv. 2012 Jan;63(1):73–78.
   PubMed Web of Science ®Google Scholar
• Fursland A, Watson HJ. Eating disorders: a hidden phenomenon in outpatient mental health? Int J Eat Disord. 2014 May;47(4):422–425.
   PubMed Web of Science ®Google Scholar
• Hudson JI, Hiripi E, Pope HG Jr., et al. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psych. 2007 Feb 01; 61(3):348–358.
   PubMed Web of Science ®Google Scholar
• Micali N, Martini MG, Thomas JJ, et al. Lifetime and 12-month prevalence of eating disorders amongst women in mid-life: a population-based study of diagnoses and risk factors. BMC Med. 2017 Jan 17;15(1):12.
   PubMedGoogle Scholar
• de Jong M, Korrelboom K, van der Meer I, et al. Effectiveness of enhanced cognitive behavioral therapy (CBT-E) for eating disorders: study protocol for a randomized controlled trial. Trials. 2016 Dec 03;17(1):573.
   PubMedGoogle Scholar
• Wilson GT, Fairburn CG. Cognitive treatments for eating disorders. J Consult Clin Psychol. 1993 Apr;61(2):261–269.
   PubMed Web of Science ®Google Scholar
• Murphy R, Straebler S, Cooper Z, et al. Cognitive behavioral therapy for eating disorders. Psych Clin North Am. 2010 Sep;33(3):611–627.
   PubMed Web of Science ®Google Scholar
• Gorla K, Mathews M. Pharmacological treatment of eating disorders. Psychiatry (Edgmont). 2005 Jun;2(6):43–48.
   PubMedGoogle Scholar
• Brambilla F, Amianto F, Dalle Grave R, et al. Lack of efficacy of psychological and pharmacological treatments of disorders of eating behavior: neurobiological background. BMC Psych. 2014 Dec 24;14:376.
   PubMed Web of Science ®Google Scholar
• Brambilla F, Draisci A, Peirone A, et al. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 2. Anorexia nervosa–binge-eating/purging type. Neuropsychobiology. 1995;32(2):64–67.
   PubMed Web of Science ®Google Scholar
• Brambilla F, Draisci A, Peirone A, et al. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 1. Anorexia nervosa–restricted type. Neuropsychobiology. 1995;32(2):59–63.
   PubMed Web of Science ®Google Scholar
• Claudino AM, Hay P, Lima MS, et al. Antidepressants for anorexia nervosa. Cochrane Database Syst Rev. 2006 Jan;25(1):CD004365.
   Google Scholar
• Agras WS, Rossiter EM, Arnow B, et al. Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison. Am J Psych. 1992 Jan;149(1):82–87.
   PubMed Web of Science ®Google Scholar
• Grilo CM, Reas DL, Mitchell JE. Combining pharmacological and psychological treatments for binge eating disorder: current status, limitations, and future directions. Curr Psych Rep. 2016 Jun;18(6):55.
   PubMed Web of Science ®Google Scholar
• Klingberg S, Herrlich J, Wiedemann G, et al. Adverse effects of cognitive behavioral therapy and cognitive remediation in schizophrenia: results of the treatment of negative symptoms study. J Nerv Ment Dis. 2012 Jul;200(7):569–576.
   PubMed Web of Science ®Google Scholar
• Fuller RW, Perry KW, Molloy BB. Effect of an uptake inhibitor on serotonin metabolism in rat brain: studies with 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine (Lilly 110140). Life Sci. 1974 Sep 15;15(6):1161–1171.
   PubMed Web of Science ®Google Scholar
• Messing RB, Phebus L, Fisher LA, et al. Analgesic effect of fluoxetine hydrochloride (Lilly 110140), a specific inhibitor of serotonin uptake. Psychopharmacol Commun. 1975;1(5):511–521.
   PubMedGoogle Scholar
• Broekkamp CL, Garrigou D, LLoyd KG. Serotonin-mimetic and antidepressant drugs on passive avoidance learning by olfactory bulbectomised rats. Pharmacol Biochem Behav. 1980 Nov;13(5):643–646.
   PubMed Web of Science ®Google Scholar
• Garrigou D, Broekkamp CL, Lloyd KG. Involvement of the amygdala in the effect of antidepressants on the passive avoidance deficit in bulbectomised rats. Psychopharmacology (Berl). 1981;74(1):66–70.
   PubMed Web of Science ®Google Scholar
• Company EL. PROZAC (fluoxetine hydrochloride) for oral use. Package Insert. 2017;1–25.
   Google Scholar
• Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Fluoxetine Bulimia Nervosa Collaborative Study Group. Arch Gen Psych. 1992 Feb;49(2):139–147.
   PubMedGoogle Scholar
• Goldstein DJ, Wilson MG, Thompson VL, et al. Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group. British J Psych. 1995 May;166(5):660–666.
   Google Scholar
• Romano SJ, Halmi KA, Sarkar NP, et al. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psych. 2002 Jan;159(1):96–102.
   PubMed Web of Science ®Google Scholar
• Aigner M, Treasure J, Kaye W, et al. Disorders WTFOE. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psych. 2011 Sep;12(6):400–443.
   PubMed Web of Science ®Google Scholar
• Aronoff GR, Bergstrom RF, Pottratz ST, et al. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther. 1984 Jul;36(1):138–144.
   PubMed Web of Science ®Google Scholar
• Sommi RW, Crismon ML, Bowden CL. Fluoxetine: a serotonin-specific, second-generation antidepressant. Pharmacotherapy. 1987 Jan-Feb;7(1):1–15.
   PubMed Web of Science ®Google Scholar
• Ceccherini-Nelli A, Guidi L. Fluoxetine: the relationship between response, adverse events, and plasma concentrations in the treatment of bulimia nervosa. Int Clin Psychopharmacol. Winter 1993;8(4):311–313.
   PubMed Web of Science ®Google Scholar
• Musher JS. Anorgasmia with the use of fluoxetine. Am J Psych. 1990 Jul;147(7):948.
   PubMed Web of Science ®Google Scholar
• Goldbloom DS, Kennedy SH. Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa. J Clin Psych. 1991 Jun;52(6):261–262.
   Google Scholar
• McElroy SL, Hudson J, Ferreira-Cornwell MC, et al. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology. 2016 Apr;41(5):1251–1260.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psych. 2015 Mar;72(3):235–246.
   PubMed Web of Science ®Google Scholar
• Gasior M, Hudson J, Quintero J, et al. A phase 3, multicenter, open-label, 12-month extension safety and tolerability trial of lisdexamfetamine dimesylate in adults with binge eating disorder. J Clin Psychopharmacol. 2017 Jun;37(3):315–322.
   PubMed Web of Science ®Google Scholar
• Hudson JI, McElroy SL, Ferreira-Cornwell MC, et al. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psych. 2017 Sep;74(9):903-910
   Web of Science ®Google Scholar
• Adler LA, Alperin S, Leon T, et al. Pharmacokinetic and pharmacodynamic properties of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017 Mar;27(2):196–199.
   PubMed Web of Science ®Google Scholar
• Ermer J, Haffey MB, Richards C, et al. Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. Neuropsychiatr Dis Treat. 2013;9:219–229.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson JI, Gasior M, et al. Time course of the effects of lisdexamfetamine dimesylate in two phase 3, randomized, double-blind, placebo-controlled trials in adults with binge eating disorder. Int J Eat Disord. 2017 Aug;50(8):884–892.
   PubMed Web of Science ®Google Scholar
• Shire. VYVANSE (lisdexamfetamine dimesylate) capsules, for oral use, CII. Package Insert. 2015;1–36.
   Google Scholar
• Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. 2009 Jun;23(4):419–427.
   PubMed Web of Science ®Google Scholar
• Pitman JT, Harris NS. Possible association with amphetamine usage and development of high altitude pulmonary edema. Wilderness Environ Med. 2012 Dec;23(4):374–376.
   PubMed Web of Science ®Google Scholar
• Attia E, Kaplan AS, Walsh BT, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med. 2011 Oct;41(10):2177–2182.
   PubMed Web of Science ®Google Scholar
• Barbarich NC, McConaha CW, Gaskill J, et al. An open trial of olanzapine in anorexia nervosa. J Clin Psych. 2004 Nov;65(11):1480–1482.
   Google Scholar
• Duvvuri V, Cromley T, Klabunde M, et al. Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa. Int J Eat Disord. 2012 Mar;45(2):294–297.
   PubMed Web of Science ®Google Scholar
• Mehler C, Wewetzer C, Schulze U, et al. Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases. Eur Child Adolesc Psych. 2001 Jun;10(2):151–157.
   PubMed Web of Science ®Google Scholar
• Dold M, Aigner M, Klabunde M, et al. Second-generation antipsychotic drugs in Anorexia nervosa: a meta-analysis of randomized controlled trials. Psychother Psychosom. 2015 Feb 21;84(2):110–116.
   PubMed Web of Science ®Google Scholar
• Guillaume S, Jaussent I, Olie E, et al. Characteristics of suicide attempts in anorexia and bulimia nervosa: a case-control study. PLoS One. 2011;6(8):e23578.
   PubMed Web of Science ®Google Scholar
• Huas C, Caille A, Godart N, et al. Factors predictive of ten-year mortality in severe anorexia nervosa patients. Acta Psychiatr Scand. 2011 Jan;123(1):62–70.
   PubMed Web of Science ®Google Scholar
• Association AP. Diagnostic and statistical manual of mental disorders: DSM-V. 5th ed. Washington (DC): American Psychiatric Association; 2013.
   Google Scholar